Placeholder text

Go to cart

IMMUNOTHERAPY IN ORAL SQUAMOUS CELL CARCINOMA

By Akanchha Singh

IMMUNOTHERAPY IN ORAL SQUAMOUS CELL CARCINOMA Medicine

IMMUNOTHERAPY IN ORAL SQUAMOUS CELL CARCINOMA

0 - Default Title
Description
Immunotherapy has emerged as a promising treatment modality for oral squamous cell carcinoma (OSCC), especially in advanced and recurrent cases where conventional therapies offer limited survival benefits. By harnessing the body's immune system, immunotherapeutic approaches such as immune checkpoint inhibitors-particularly anti-PD-1 agents like nivolumab and pembrolizumab-have shown improved overall survival and quality of life in select OSCC patients, as demonstrated in landmark trials like KEYNOTE-048 and CheckMate 141. Other strategies, including cancer vaccines, adoptive cell therapy, cytokine therapy, and oncolytic viruses, are under investigation but have yet to achieve widespread clinical use. Despite these advances, challenges such as low response rates, immune-related adverse events, tumor heterogeneity, and resistance mechanisms limit the efficacy of immunotherapy. Biomarkers like PD-L1 expression, tumor mutational burden, and immune gene signatures are being explored to guide patient selection and predict response. Combination therapies with chemotherapy, radiotherapy, or other immunomodulators are being developed to enhance outcomes.
Product details
Binding:
Paperback
Number of Pages:
108
Release Date:
2025-05-30
Publication Date:
2025-05-30
Publisher:
LAP LAMBERT Academic Publishing
Languages:
Original: English
ISBN10:
6205632411
ISBN13:
9786205632413
Weight:
179 g
Height:
150 cm
Width:
220 cm
Thickness:
7 cm
Buy on Amazon
Currently sold out